Sanders, who is running for the Democratic candidacy, declined to accept the $2,700 donation Ms. Shkreli tried to make. He asserted that he got inspiration to contribute; the maximum sum an individual can donate to a campaign, by Sanders’ platform, but admitted to the Stat that the key motive behind the move was to meet Sanders to explain him how his and other pharmaceutical companies decide drug prices.
Advertisement
However, a campaign spokesperson, Michael Briggs, told Stat, ‘We are not keeping the money from this poster boy for drug company greed’.
A single tweet from Hillary Clinton on September 21 that said she would propose a strategy for counteracting “price-gouging” by pharma firms sent biotech stocks into a tailspin. Instead, it will be redirected to a health clinic and social advocacy effort in Washington D.C known as Whitman-Walker, which largely provides services regarding HIV/AIDS.
Each contributor to the Bernie Sanders campaign can look forward to a form letter response.
Meanwhile, Shkreli has responded to Sanders’ rejection with about as much maturity as he’s addressed all of his critics so far. The drug is used to fight life threatening parasitic infections and can be important to AIDS and cancer patients, including infants.
The donation was more than a little odd given Sander’s open hostility to the pharmaceutical CEO.
Mr. Shkreli said he was “furious” that Sen.
The pharmaceutical executive told the Boston Globe he agreed with numerous Democratic presidential candidate’s positions, though notably not Sanders’ ideas about lowering drug prices.
He said that if given the chance he would like to ask Sanders if he understood that drug companies sometimes need to charge high prices in order to pay for life-saving pharmaceutical developments.
Damn @BernieSanders is my boy with that Kosovo reference.
Advertisement
“Would you prefer (1) a lower price of our medicine, which is overwhelming paid for by “corporate America” and their insurers (who are reporting record profts) or (2) that we use our resources to research a new drug for resistant strains of this neglected disease”.
